Get started
Author

Ishani Savant Landry

Observed names: I Landry, Ishani Landry, Ishani S. Landry, Ishani Savant‐Landry, Landry, Ishani
ORCID: 0000-0002-4865-4754
Observed ORCID: 0000-0002-4865-4754
OpenAlex ID: A5002542527
On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
2018 · Annemiek Vermeeren, Stefan Jongen, et al. · SLEEP · 230
PDF
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults
2020 · Ishani Landry, Kenya Nakai, et al. · Clinical Pharmacology in Drug Development · 72
PDF
Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
2022 · Seiichi Hayato, Osamu Takenaka, et al. · CPT Pharmacometrics & Systems Pharmacology · 42
PDF
Bioanalysis of dried saliva spot (DSS) samples using detergent-assisted sample extraction with UHPLC-MS/MS detection
2016 · Naiyu Zheng, Jianing Zeng, et al. · Analytica Chimica Acta · 33
Pharmacokinetic Interactions between BMS-626529, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug BMS-663068, and Ritonavir or Ritonavir-Boosted Atazanavir in Healthy Subjects
2015 · Li Zhu, Matthew Hruska, et al. · Antimicrobial Agents and Chemotherapy · 29
PDF
Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users
2022 · Ishani Landry, Nancy Hall, et al. · Journal of Clinical Psychopharmacology · 28
The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act
2023 · Margaret Moline, Shoji Asakura, et al. · Psychopharmacology · 25
PDF
Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant
2021 · Ishani Landry, Jagadeesh Aluri, et al. · Clinical Pharmacology in Drug Development · 23
PDF
Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
2020 · Bojan Lalovic, Oneeb Majid, et al. · The Journal of Clinical Pharmacology · 22
PDF
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529
2016 · Ishani Landry, Li Zhu, et al. · Antimicrobial Agents and Chemotherapy · 21
ECG Evaluation as Part of the Clinical Pharmacology Strategy in the Development of New Drugs: A Review of Current Practices and Opportunities Based on Five Case Studies
2022 · Borje Darpo, Marie Borin, et al. · The Journal of Clinical Pharmacology · 15
Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors
2021 · Takashi Ueno, Yukiko Miyajima, et al. · CPT Pharmacometrics & Systems Pharmacology · 14
PDF
Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study
2022 · Ishani Landry, Nancy Hall, et al. · Journal of Psychopharmacology · 12
Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial
2022 · Ishani S. Landry, Jagadeesh Aluri, et al. · Alzheimer Disease & Associated Disorders · 11
Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
2021 · Ishani Landry, Jagadeesh Aluri, et al. · Pharmacology Research & Perspectives · 11
Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant
2020 · Ishani Landry, Jagadeesh Aluri, et al. · Pharmacology Research & Perspectives · 11
PDF
Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users
2022 · Ishani Landry, Nancy Hall, et al. · Journal of Clinical Psychopharmacology · 10
Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
2021 · Satish Dayal, Jagadeesh Aluri, et al. · Pharmacology Research & Perspectives · 8
PDF
O013 Preliminary Results from a Phase 1 Study of ALKS 2680, an Orexin-2 receptor Agonist, in Healthy Participants and Patients with Narcolepsy or Idiopathic Hypersomnia
2023 · B Yee, J Chapman, et al. · SLEEP Advances · 6
PDF
Lecanemab (BAN2401) Infusion Reactions and Immunogenicity: Results from Randomized Phase 2 Study and an Open‐Label Extension (OLE).
2022 · Ishani Landry, Michio Kanekiyo, et al. · Alzheimer s & Dementia · 5
Exposure–Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia
2022 · Bojan Lalovic, Ishani Savant Landry, et al. · The Journal of Clinical Pharmacology · 3
Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Lecanemab in Healthy Subjects
2022 · Sumit Rawal, Anh Duong, et al. · Alzheimer s & Dementia · 2
Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug‐Drug Interaction Study in Healthy Females
2021 · Ishani Landry, Jagadeesh Aluri, et al. · Clinical Pharmacology in Drug Development · 2
[p1–056]: Population Pharmacokinetic‐pharmacodynamic (pk/pd) Modeling of E2027, a Selective Phosphodiesterase‐9 (pde9) Inhibitor, Following Single Ascending Oral Doses in Healthy Volunteers
2017 · Edgar L. Schuck, Robert Y.K. Lai, et al. · Alzheimer s & Dementia · 2
3.12 Olanzapine and Samidorphan in Pediatric Patients With Bipolar I Disorder: Pharmacokinetic Results From a Phase 1, Multidose, Open-Label Study
2024 · Melissa P. DelBello, Liming Zhang, et al. · Journal of the American Academy of Child & Adolescent Psychiatry · 1
PDF
Works count: 35
Citation count: 641
H-index: 12
I10-index: 17
Year
Topic
Type